Sesen Bio (NASDAQ: SESN) is one of 519 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it compare to its rivals? We will compare Sesen Bio to related companies based on the strength of its dividends, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk.
Insider & Institutional Ownership
52.1% of Sesen Bio shares are held by institutional investors. Comparatively, 46.9% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 21.0% of Sesen Bio shares are held by company insiders. Comparatively, 15.4% of shares of all “Pharmaceutical preparations” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Volatility & Risk
Sesen Bio has a beta of 2.59, indicating that its stock price is 159% more volatile than the S&P 500. Comparatively, Sesen Bio’s rivals have a beta of 0.95, indicating that their average stock price is 5% less volatile than the S&P 500.
Earnings & Valuation
This table compares Sesen Bio and its rivals top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Sesen Bio||$430,000.00||-$29.02 million||-1.93|
|Sesen Bio Competitors||$1.97 billion||$128.10 million||-9.12|
Sesen Bio’s rivals have higher revenue and earnings than Sesen Bio. Sesen Bio is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
This is a summary of current recommendations for Sesen Bio and its rivals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Sesen Bio Competitors||3541||10413||24056||771||2.57|
Sesen Bio currently has a consensus price target of $3.75, indicating a potential upside of 75.23%. As a group, “Pharmaceutical preparations” companies have a potential upside of 40.54%. Given Sesen Bio’s stronger consensus rating and higher possible upside, analysts plainly believe Sesen Bio is more favorable than its rivals.
This table compares Sesen Bio and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Sesen Bio Competitors||-2,947.84%||-94.64%||-27.54%|
Sesen Bio beats its rivals on 9 of the 13 factors compared.
About Sesen Bio
Sesen Bio, Inc., a late-stage clinical company, develops next-generation antibody-drug conjugate therapies for patients with cancer. It develops its products based on its Targeted Protein Therapeutics (TPTs) platform. The company's lead product candidate is Vicinium, a fusion protein that is in Phase III clinical trial for the treatment of high-grade non-muscle invasive bladder cancer. It also develops Vicinium in combination with Durvalumab, which is in Phase I clinical trial for the treatment of high-grade non-muscle invasive bladder cancer; and Vicinium in combination with AstraZeneca's checkpoint inhibitor for the treatment of squamous cell carcinoma of the head and neck. In addition, the company is developing systemically-administered TPTs, including VB6-845d for the treatment of solid tumors. The company was formerly known as Eleven Biotherapeutics, Inc. and changed its name to Sesen Bio, Inc. in May 2018. Sesen Bio, Inc. was founded in 2008 and is based in Cambridge, Massachusetts.
Receive News & Ratings for Sesen Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sesen Bio and related companies with MarketBeat.com's FREE daily email newsletter.